Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.271 -0.039 (-2.99%)
Streaming Delayed Price Updated: 12:03 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Atai Life Sciences N.V.

< Previous 1 2 3 Next >
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Colorado to Vote on Legalizing Psychoactives in November
Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the... 
Via PressReach
Topics Supply Chain
Exposures Supply Chain
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
Via PressReach
Topics Cannabis
Exposures Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
Exposures Cannabis
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
From atai Life Sciences
Via GlobeNewswire
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one week after San Francisco officially decriminalized psychedelics, a meeting was held by the City... 
Via PressReach
Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 22, 2022 – Atlanta just became the latest city to consider decriminalizing psychedelics. On September 12, just one... 
Via FinancialNewsMedia
Psychedelics Use Among Young Adults Reaches All-Time High
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey,... 
Via FinancialNewsMedia
Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 10, 2022 – Toronto’s Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study... 
Via FinancialNewsMedia
Topics Supply Chain
Exposures Supply Chain
InvestorNewsBreaks – Atai Life Sciences (NASDAQ: ATAI) Featured in Analysis Report
Via Investor Brand Network
Topics Derivatives
Exposures Derivatives
American Billionaire Entrepreneurs Bet Millions on Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman... 
Via FinancialNewsMedia
Exposures Product Safety
Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders
Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam... 
Via FinancialNewsMedia
Topics Law Enforcement
Exposures Legal
Roth Capital Reveals Top Psychedelic Picks in New Industry Report
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report... 
Via FinancialNewsMedia
New Research Reveals How Psychedelics Are Helping Combat Mental Illness
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – March 29, 2022 – Mental health cases are continuing to rise and are taking a serious toll on the healthcare system. Luckily,... 
Via FinancialNewsMedia
Atai Life Sciences N.V. (NASDAQ: ATAI) Featured in Virtual Coverage of the 34th Annual Roth Conference
Via Investor Brand Network
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric... 
Via FinancialNewsMedia
Topics Economy
Exposures Economy
NetworkNewsAudio – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Differentiates Itself in Psychedelics Space
Via Investor Brand Network
Psychedelic Therapies Offer Hope for Mental Health
Via Investor Brand Network
Psychedelic Therapies Offer Hope for Mental Health
Via Investor Brand Network
Psychedelic Therapies Offer Hope for Mental Health
NetworkNewsWire Editorial Coverage New York, NY – March 2, 2022 – Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of... 
Via FinancialNewsMedia
Psilocybin and MDMA Get the Green Light for Medical Use in Canada
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – January 19, 2022 – After facing legal scrutiny for decades, psychedelics including MDMA and psilocybin received a stamp of... 
Via FinancialNewsMedia
A Recap of How Psychedelics Fared in 2021
Via Investor Brand Network
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept... 
Via FinancialNewsMedia
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways
Via Investor Brand Network
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion... 
Via FinancialNewsMedia
NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon
Via Investor Brand Network
Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”,... 
Via FinancialNewsMedia
Topics Law Enforcement
Exposures COVID-19 Legal
Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More
Via Investor Brand Network
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
Exposures Product Safety
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.